IRIDEX Corporation’s (IRIX) “Buy” Rating Reiterated at Roth Capital
IRIDEX Corporation (NASDAQ:IRIX)‘s stock had its “buy” rating reiterated by equities research analysts at Roth Capital in a research report issued to clients and investors on Friday.
Separately, Zacks Investment Research lowered shares of IRIDEX Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th.
IRIDEX Corporation (NASDAQ:IRIX) last released its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). IRIDEX Corporation had a negative net margin of 42.22% and a negative return on equity of 22.65%. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $10.48 million.
WARNING: “IRIDEX Corporation’s (IRIX) “Buy” Rating Reiterated at Roth Capital” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/03/iridex-corporation-irix-now-covered-by-analysts-at-roth-capital.html.
Hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new stake in shares of IRIDEX Corporation in the second quarter valued at about $196,000. LMR Partners LLP purchased a new stake in shares of IRIDEX Corporation in the second quarter valued at about $242,000. Ingalls & Snyder LLC purchased a new stake in shares of IRIDEX Corporation in the third quarter valued at about $234,000. Goldman Sachs Group Inc. purchased a new stake in shares of IRIDEX Corporation in the second quarter valued at about $607,000. Finally, Osborne Partners Capital Management LLC purchased a new stake in shares of IRIDEX Corporation in the third quarter valued at about $673,000. Institutional investors own 48.30% of the company’s stock.
IRIDEX Corporation Company Profile
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
Receive News & Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related companies with MarketBeat.com's FREE daily email newsletter.